Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

A pilot study of the pan-class I PI3K inhibitor buparlisib in combination with cetuximab in patients with recurrent or metastatic head and neck cancer.

Brisson RJ, Kochanny S, Arshad S, Dekker A, DeSouza JA, Saloura V, Vokes EE, Seiwert TY. A pilot study of the pan-class I PI3K inhibitor buparlisib in combination with cetuximab in patients with recurrent or metastatic head and neck cancer. Head Neck. 2019 11; 41(11):3842-3849.

View in: PubMed

collapse authors with profiles